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A method of producing a soybean-based biomaterial Which is 
suitable for use in a biomedical product, the method compris 
ing: defatting soy ?our; either prior to or at the same time as, 
performing a solvent extraction; to produce a biomaterial 
comprising variable levels of soy proteins, carbohydrates and 
iso?avones. The resulting biomaterials have a range of bio 
medical uses and are particularly desirable because of their 
iso?avone content. Examples of biomedical products con 
taining the biomaterials include Wound dressings; scaffolds 
for tissue engineering; ?llers or implants for use in surgery; 
temporary barriers for use in dental or surgical procedures or 
to prevent post-surgical tissue adherence; carriers for the 
delivery of drugs, bioactive peptides orplasmids; anti-in?am 
matory agents; coatings for Wound dressings or for dental, 
medical, surgical or veterinary devices or implants; and com 
positions for soothing skin or gum irritation. 
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BIOACTIVE AND RESORBABLE 
SOYBEAN-BASED BIOMATERIALS 
[0001] This invention relates to a method for producing 
soybean-based biomaterials. The resulting biomaterials have 
a range of biomedical uses and are particularly desirable 
because of their iso?avone content. 
[0002] As understood by persons skilled in the art, a bio 
material is a non-viable material used in a medical device 
(such as an implant) intended to interact With biological sys 
tems. The future of regenerative medicine closely depends on 
the availability of novel biomaterials able to (i) intervene in 
the tissue regeneration processes and enhance the formation 
of neW tissue shoWing physiological morphology and (ii) 
degrade in time leaving space to the neWly-formed tissue. 
None of the available biomaterials is able to ful?l these obj ec 
tives unless very expensive and unstable groWth factors are 
loaded into the material bulk and their controlled delivery 
optimised, or unless stem and differentiated cells are encap 
sulated (1, 2). 
[0003] The regeneration of soft tissues (e.g. blood vessels 
and skin) as Well as of hard tissues (i.e. bone and cartilage) has 
been pursued so far by the use of synthetic or natural poly 
mers and ceramics able to provide a scaffold for the in-groWth 
of neW tissue at the site of injury (2, 3 and 4). HoWever, the 
currently available biomaterials are not able to act selectively 
on the main phases of the tissue regeneration process Which 
are: (i) the coagulation cascade, (ii) the in?ammatory 
response, (iii) the tissue cell differentiation and (iv) the syn 
thesis of neW extra-cellular matrix. 
[0004] In addition, the presence of the implant, recognised 
as a foreign body by the host tissue, normally triggers an 
in?ammatory response (5). As a consequence of this foreign 
body response, (i) permanent implants are not alWays com 
pletely integrated With the groWing tissue, but they are encap 
sulated by a ?brous capsule; and (ii) the biodegradation/ 
bioresorption rate of temporary implants may be affected and 
not in tune With the groWth rate of the neW tissue. The latter is 
the case With the biodegradable biomaterials accepted by the 
Food and Drug Administration, such as the various formula 
tions of poly(lactic/ glycolic) acids (PGLA) (6). In the case of 
bone applications, for example, the relatively sloW degrada 
tion of PGLA delays tissue regeneration (7). Even When the 
degradation time is reduced as in the case of some PGLA 
formulations, the morphology of the bone formed around the 
implant shoWs non-physiological features (i.e. cortical bone 
in place of trabecular bone) suggesting an altered mechanism 
of tissue regeneration (7). The non-physiological healing 
observed after implantation of these materials has also been 
ascribed to the in?ammatory response elicited by the material 
surface physico-chemical properties and, in the case of 
PGLA, to the degradation products (8). 
[0005] Ceramics such as hydroxyapatite (HA), calcium 
phosphate (CaP) cements and bioglasses have also been 
developed mainly for bone regeneration applications. 
Although not biodegradable, these materials have shoWn a 
high osteointegrative potential (9, 10). In the case of HA and 
CaP cements, the osteointegrative potential seems to be gen 
erated by the material cell substrate properties Which alloW 
the colonisation of the surface by the bone cells, the osteo 
blasts (11). 
[0006] In the case of bioglasses, a degree of bioactivity has 
been ascribed either to the release of elements (eg silicon) 
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from the degrading material or by the entrapment and con 
centration of groWth factors in the gel milieu formed at the 
interface during the bioglass degradation (12). 
[0007] The performances of the ceramic materials are, 
hoWever, limited only to certain applications because of their 
brittle and not malleable nature. Monolithic ceramics are 
di?icult to handle during the implantation procedure, While 
ceramic coatings delaminate under the mechanical loadings 
(9, 13). 
[0008] Natural polymers of protein or polysaccharide com 
position such as collagen, agarose, alginate, chitosan, ?brin 
glue, silk ?broin, hyaluronic acid and carboxymethylcellu 
lose are also used as biodegradable biomaterials and some of 
them have been shoWn to have haemo static properties and to 
support cell adhesion (14, 15 and 16). Fibrin glue, hyaluronic 
acid and collagen are natural components of a regenerating 
tissue and their performances in biomedicine have been dem 
onstrated (14). HoWever, concerns about their use as bioma 
terials are raised by their antigenic potential, by the risks of 
transmittable diseases and by the relatively high manufactur 
ing costs. In the speci?c case of bone ?llers, risks of trans 
mittable diseases are also linked to the use of bone allografts, 
While autografts lead to a second operation on the patient at 
different sites to harvest bone and With limitations in the 
amounts available. 
[0009] The use of soy-based biomaterials has also been 
suggested (17, 18). The research has been oriented toWards 
the manufacture of soy protein hydrogels, ?lms, membranes 
and ?bres from the soybean protein fractions (18). Although 
very malleable, this type of biomaterial suffers from the same 
limitations as the other natural, biodegradable polymers; 
mainly an antigenic potential and an uncontrolled (not tune 
able) rate of degradation (19). Furthermore, they do not 
include the iso?avone fraction Which has a proven bioactivity 
on both immunocompetent cells and tissue cells such as 
osteoblasts and osteoclasts (20, 21). A patent has been ?led 
that covers the use of genistein, one of the soy iso?avones, as 
a pharmaceutical agent to reduce bone loss in osteoporosis by 
inhibiting osteoclast acid activity (21). 
[0010] For these reasons, more recently, a neW class of 
soy-based biomaterials has been developed using de-fatted 
soybean curd Which includes all the components of the soy: 
proteins, carbohydrates, minerals and iso?avones (22). This 
class of biomaterial can be formulated as ?lms, membranes 
and granules either as a monolithic material or in combination 
With other conventional biomaterials. Moreover, this neW 
class of soy-based biomaterials and their degradation prod 
ucts have shoWn many properties suitable for biomedical 
applications among Which are to: (i) control the in?ammatory 
response, (ii) have a controlled (tuneable) rate of degradation, 
(iii) favour cell activity and (iv) induce the deposition of a 
calcium phosphate mineral phase (22). 
[0011] Although the soy protein-based biomaterials have 
been engineered in the form of hydrogels, ?lms and ?bres, 
they lack the recognised bioactivity of the soy iso?avones on 
tissue cells. Conversely, the soy-based biomaterials obtained 
from the de-fatted soybean curd-derived biomaterials have 
not been thus far formulated in the form of soft hydrogels 
suitable, for example, for implantation by injection. In addi 
tion, their method of manufacture depends on the preliminary 
preparation of a curd and it relies on the natural soybean 
iso?avone content Without the possibility of modifying its 
levels. 







